BridgeMD
Tests treatment safety and results for Rheumatic Arthritis
Official title Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.
ClinicalTrials.gov ID: NCT07089381
What this study is testing
What is Methotrexate?
Methotrexate is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for rheumatic arthritis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis. Objectives : 1.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult patients \> 18 years old
- Established diagnosis of RA according to American College of Rheumatology/European league Against Rheumatism (ACR/EULAR) 2010 criteria (Aletaha et...
- Patients receiving stable regimen of one or more csDMARDs for at least the past 3 months.
- RA Patients with Moderate or high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP)...
You likely can't join if
- Patients receiving biologic DMARDs therapy for RA
- Patients taking any other anti-inflammatory drugs
- Patients taking any other antioxidants
- Pregnant and lactating women
- Other rheumatological, inflammatory diseases or malignancies
- Smokers
See the full eligibility criteria
- Adult patients \> 18 years old
- Established diagnosis of RA according to American College of Rheumatology/European league Against Rheumatism (ACR/EULAR) 2010 criteria (Aletaha et al., 2010), presented with moderate to high disease activity identified...
- Patients receiving stable regimen of one or more csDMARDs for at least the past 3 months.
- RA Patients with Moderate or high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \>3.2.
- Patients receiving biologic DMARDs therapy for RA
- Patients taking any other anti-inflammatory drugs
- Patients taking any other antioxidants
- Pregnant and lactating women
- Other rheumatological, inflammatory diseases or malignancies
- Smokers
- Thyroid illnesses
- Patients with impaired liver functions (liver transaminases level ≥ three times upper normal limits), impaired kidney functions (estimated glomerular filtration rate (eGFR) \< 30 ml/min)
The study team makes the final eligibility decision.
Where it's taking place
- Cairo, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cairo, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.